RecruitingNCT06490926

NMR Based Metabolomic Study of Serum Biomarkers in Patients With Parkinson's Disease and Atypical Parkinsonian Syndrome

Sponsor

Fujian Medical University Union Hospital

Enrollment

180 participants

Start Date

Feb 1, 2023

Study Type

OBSERVATIONAL

Conditions

Multiple System Atrophy Progressive Supranuclear Palsy Parkinson's Disease

Summary

At present, the diagnosis of Parkinsons disease(PD) mainly relies on clinical symptoms and is easily confused with atypical Parkinsonian syndrome(APS) in the early stages. There is an urgent need for reliable biomarkers. This project aims to use metabolomics technology based on proton nuclear magnetic resonance spectroscopy to study the metabolomic characteristics of patients with PD and APS, and preliminarily screen for possible diagnostic biomarkers of PD and APS.

Eligibility

Min Age: 45 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is analyzing blood samples (specifically metabolites found in the blood using NMR technology) from people with Parkinson's disease and related conditions like multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). Researchers want to find biological markers in the blood that can help distinguish these conditions and track their progression. **You may be eligible if...** - You are between 45 and 80 years old - You have a confirmed diagnosis of Parkinson's disease, MSA, or PSP according to established diagnostic criteria - You are willing to provide blood samples **You may NOT be eligible if...** - You have another serious neurological or systemic disease that could confound results - You are unable to provide informed consent - You have recently taken medications that could significantly affect metabolite levels Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.